CytomX halts lead program and will seek a partner as breast cancer drug disappoints

Mixed Phase II results are forcing CytomX to slam the brakes on one of its lead cancer drugs — unless it can convince a partner to help take it further.

The data come from a study of praluzatamab ravtansine, CytomX’s take on a CD166-targeting antibody-drug conjugate, in breast cancer that…